Identification and characterization of circulating prostate carcinoma cells

Wang, Zhengpin; Eisenberger, Mario A.; Carducci, Michael A.; Partin, Alan W.; Scher, Howard I.; Ts’o, Paul O. P.

doi:10.1002/1097-0142(20000615)88:12<2787::aid-cncr18>3.0.co;2-2

Cited by 81 publications

(67 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, CTC debris can be observed in patients with large numbers of CTC that have not been immunomagnetically enriched (42). The presence of apoptotic bodies near the tumor site and in the blood stream are reported by others (17,(43)(44)(45)(46) as well as an increase of cytokeratin 18, 19 and caspase cleaved cytokeratin in serum of patients with carcinomas (47)(48)(49)(50)(51)(52) supporting the notion that the detected tumor debris is indeed directly related to the presence of a tumor. A recent retrospective analysis of EpCAM …”

Section: Discussionsupporting

confidence: 53%

Automated identification of circulating tumor cells by image cytometry

Scholtens

Schreuder

Ligthart³

et al. 2011

Cytometry Pt A

View full text Add to dashboard Cite

Presence of circulating tumor cells (CTC), as detected by the CellSearch 1 System, in patients with metastatic carcinomas is associated with poor survival prospects. CellTracks TDI, a dedicated image cytometer, was developed to improve the enumeration of these rare CTC. The CellSearch System was used to enumerate CTC in 7.5 mL blood of 68 patients with cancer and 9 healthy controls. Cartridges containing the fluorescently labeled CTC from this system were reanalyzed using the image cytometer, which acquires images with a TDI camera using a 403/0.6 NA objective and lasers as light source. Automated classification of events was performed by the Random Forest method using Matlab. An automated classifier was developed to classify events into CTC, apoptotic CTC, CTC debris, leukocytes, and debris not related to CTC. A high agreement in classification was obtained between the automated classifier and five expert reviewers. Comparison of images from the same events in CellTracks TDI and CellTracks Analyzer II shows improved resolution in fluorescence images and improved classification by adding bright-field images. Improved detection efficiency for CD45-APC avoids the classification of leukocytes nonspecifically binding to cytokeratin as CTC. The correlation between number of CTC detected in CellTracks TDI and CellTracks Analyzer II is good with a slope of 1.88 and a correlation coefficient of 0.87. Automated classification of events by CellTracks TDI eliminates the operator error in classification of events as CTC and permits quantitative assessment of parameters. The clinical relevance of various CTC definitions can now be investigated. '

show abstract

Section: Discussionsupporting

confidence: 53%

Automated identification of circulating tumor cells by image cytometry

Scholtens

Schreuder

Ligthart³

et al. 2011

Cytometry Pt A

View full text Add to dashboard Cite

show abstract

“…One possible method to monitor this possibility of residual micrometastatic disease might be the use of technology that detects circulating prostate cells, preferably cancer cells, in the blood. 15,16 More recently, a new commercially available technique already has been quite successful in breast carcinoma cases and could prove of value in patients with prostate carcinoma. 17,18 The current study analysis demonstrates that some men who fail to achieve an undetectable PSA level will experience slow disease progression and remain free of distant metastasis for an extended length of time.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, the detection of circulating prostate carcinoma cells in the blood is another technology that may facilitate the prediction of patients likely to develop distant metastases. [15][16][17][18] The limitations of the current study included the retrospective design and limited follow-up in some patients. Follow-up was limited for 47 of the patients in this study (30%) who had only 1-2 years of followup after undergoing RRP.…”

Section: Discussionmentioning

confidence: 99%

Natural history of disease progression in patients who fail to achieve an undetectable prostate‐specific antigen level after undergoing radical prostatectomy

Rogers

Khan

Miller

et al. 2004

Cancer

Self Cite

View full text Add to dashboard Cite

BACKGROUNDTo the authors' knowledge, the natural history of disease progression to distant metastasis is unknown in men who fail to achieve an undetectable prostate‐specific antigen (PSA) level after radical retropubic prostatectomy (RRP),. The authors assessed the clinical outcome of men with a persistently detectable PSA level after RRP for clinically localized prostate carcinoma.METHODSBetween 1989 and 2002, 160 men failed to achieve an undetectable PSA level (≥ 0.1 ng/mL) after undergoing RRP for clinically localized prostate carcinoma. No patient received adjuvant therapy before documented metastasis. The Kaplan–Meier method was used to estimate distant metastasis‐free survival. Univariate and multivariate Cox proportional hazards regression was used to assess the ability of clinical and pathologic variables to predict distant metastasis‐free survival.RESULTSThe probability of distant metastasis‐free survival at 3 years, 5 years, and 10 years was reported to be 68%, 49%, and 22%, respectively. Seventy‐five men (47%) developed distant metastases after RRP (median time to metastases of 5.0 years; range, 0.5–13 years). The combination of RRP Gleason score, seminal vesicle status, and lymph node status resulted in 3 risk groups for the prediction of distant metastasis‐free survival (hazards ratio [HR] = 1.6; P < 0.01). The slope of PSA changes approximately 3–12 months after RRP at a cutoff value ≥ 0.05 was found to be even more predictive of distant metastasis‐free survival (HR = 2.9; P < 0.01).CONCLUSIONSMany patients remained free of metastatic disease for an extended period despite failing to achieve an undetectable PSA level after undergoing RRP for clinically localized prostate carcinoma. However, other patients experienced rapid disease progression to distant metastasis. The authors defined clinical (PSA slope) and pathologic (Gleason score) prognostic variables to help identify those patients with a higher risk of developing distant metastasis after undergoing RRP. Cancer 2004. © 2004 American Cancer Society.

show abstract

“…Molecules synthesized in cancer cells, released into the blood, and recognized as tumor markers have also been found in the blood of cancer patients. [11][12][13] All of the patients included in this study had abnormally high serum levels of tumor markers, which is evidence of disease with active release of malignant cell contents to blood. Under such circumstances, other molecules could be released by cancer cells.…”

Section: Mechanism Of Actionmentioning

confidence: 99%

Antitumoral Effect of a Vaccination Procedure with an Autologous Hemoderivative

Lasalvia-Prisco¹,

Cucchi²,

Vazquez³

et al. 2003

Cancer Biology & Therapy

View full text Add to dashboard Cite

Lately, the promising results obtained with autologous cancer vaccines are stimulating new research in the old field of cancer immunotherapy. This paper describes the development of a procedure previously reported by us that is used to obtain an autologous hemoderivative with antitumoral properties. The procedure has been tested in a phase I-II, randomized, controlled clinical trial of 28 cancer patients with different primary malignancies in metastatic and chemotherapy-resistant stages. The histology of the lesions that responded to this treatment was consistent with the characteristic histology observed in malignant lesions treated with a similar antitumoral hemoderivative: proliferation of stromal connective tissue, T-lymphocyte infiltration, and a reduction in the amount of tumor cells and blood vessels. We concluded that vaccination had elicited an immune response because a delayed-type hypersensitivity test made with the autologous hemoderivative produced a significantly more intense response in the responding treated patients. We propose that an immune mechanism acting on tumor cells and/or the regulatory system for stromal growth explains the histological results observed. The use of blood to obtain the immunogen allows vaccination to be repeated, so this method could avoid tumor escape responses due to mutations in the antigen library of the tumor. The results of our study justify further research to optimize the antitumoral effect of vaccination.

show abstract

Identification and characterization of circulating prostate carcinoma cells

Cited by 81 publications

References 5 publications

Automated identification of circulating tumor cells by image cytometry

Automated identification of circulating tumor cells by image cytometry

Natural history of disease progression in patients who fail to achieve an undetectable prostate‐specific antigen level after undergoing radical prostatectomy

Antitumoral Effect of a Vaccination Procedure with an Autologous Hemoderivative

Contact Info

Product

Resources

About